Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rosiglitazone (BRL-49653)].

N Kameda1, S Okuya, Y Oka

  • 1Yamaguchi University School of Medicine, Third Department of Internal Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

INVESTIGATION OF A PRACTICAL PATIENT DOSE INDEX FOR ASSESSMENT OF PATIENT ORGAN DOSE FROM CONE-BEAM COMPUTED TOMOGRAPHY IN RADIATION THERAPY USING A MONTE CARLO SIMULATION.

Radiation protection dosimetry·2018
Same author

Pilocytic astrocytomas in elderly adults.

The neuroradiology journal·2013
Same author

Caffeine activates preferentially α1-isoform of 5'AMP-activated protein kinase in rat skeletal muscle.

Acta physiologica (Oxford, England)·2011
Same author

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione.

Diabetologia·2006
Same author

Leptin increases the viability of isolated rat pancreatic islets by suppressing apoptosis.

Endocrinology·2001
Same author

[Effect of background factors concerning both elderly persons and their families with regard to the caregiver burnout in the home].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2001
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Rosiglitazone, an antidiabetic drug, effectively treats type 2 diabetes by improving insulin resistance. This medication lowers glucose and triglyceride levels, showing promise for managing this chronic condition.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance.
  • Thiazolidinediones are a class of antidiabetic agents.
  • Rosiglitazone is a potent thiazolidinedione derivative.

Purpose of the Study:

  • To evaluate the efficacy of rosiglitazone in improving insulin resistance in T2DM patients.
  • To assess the correlation between rosiglitazone's binding affinity to PPAR-gamma and its antidiabetic effects.
  • To investigate the effects of rosiglitazone on glycemic control and potential adverse effects.

Main Methods:

  • In vitro binding assays to determine affinity for PPAR-gamma.
  • Animal models of insulin resistance were used to assess in vivo effects.

Related Experiment Videos

  • Clinical trials involving T2DM patients treated with varying doses of rosiglitazone (2-12 mg/day).
  • Measurements included fasting plasma glucose, HbA1C, triglyceride levels, and assessment of hypoglycemia and hepatotoxicity.

    • Main Results:

    • Rosiglitazone demonstrated high binding affinity for PPAR-gamma.
    • In animal models, rosiglitazone reduced plasma glucose, triglyceride, and insulin levels, and prevented diabetic complications.
    • Clinical trials showed significant improvements in glycemic control, indicated by decreased fasting plasma glucose and HbA1C levels.
    • No increased risk of hypoglycemia or evidence of hepatotoxicity was observed in pre-clinical studies.

    Conclusions:

    • Rosiglitazone is an effective antidiabetic agent for T2DM, improving insulin resistance and glycemic control.
    • Its therapeutic potency is linked to its high PPAR-gamma binding affinity.
    • Rosiglitazone presents a favorable safety profile regarding hypoglycemia and hepatotoxicity in pre-clinical assessments.